Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22

April 11, 2023

https://www.globenewswire.com/news-release/2023/04/11/2644955/0/en/Cellectis-Announces-Dosing-of-the-First-Patient-in-Europe-with-its-In-house-Manufactured-Product-Candidate-UCART22.html

NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that the first patient in Europe has been dosed in France with its in-house manufactured product candidate UCART22 and completed the 28-day Dose Limiting Toxicity period.

Read more at globenewswire.com

Related news for (CLLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.